As a potential functional food, chitosan oligosaccharide (COS) has attracted much attention due to its outstanding biological activity. The study found that chitosan oligosaccharide COS (250 and 500 mg/kg) had a protective effect on dextran sulfate sodium (DSS)-induced chronic experimental ulcerative colitis (UC) in mice. Elevated serum and colonic tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 levels were significantly decreased in the assay. The expression of TUNEL+ apoptotic cells and Cleaved - Caspase-9 in COS-treated colon was down-regulated, while Ki-67+ proliferating cells and Bcl-2/Bax ratio were up-regulated. COS enhanced the intestinal flora diversity and restored the intestinal flora structure in chronic UC mice. The expression of colonic TLR4, NF-κB, STAT3 and pSTAT3 was significantly decreased, while the expression of regenerating islet-derived 3γ (Reg3g) was increased. The results suggest that COS is an alternative treatment option for chronic UC treatment by improving inflammation, promoting mucosal repair, and modulating gut microbiota.
Note: The chitosan oligosaccharides used in the experiment were from Qingdao BZ Oligo Biotech Co.,Ltd.
This article is taken from 《The protective role of Chitooligosaccharides against chronic ulcerative colitis induced by dextran sulfate sodium in mice》
Disclaimer: The contents of the above reprinted or quoted articles are only used for learning and research purposes. If there is any discrepancy, please correct it immediately.
BZ Oligo mainly offer marine oligosaccharide standards and ingredients, containing alginate oligosaccharide, chitosan oligosaccharide, agar oligosaccharide and carrageenan oligosaccharide, which give business opportunities using these untapped oligosaccharides for biological applications targeting lab research, pharmacy, dietary supplement, sustainable agriculture and animal health.
Factory